Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abpro Holdings Inc. stock logo
ABP
Abpro
$0.52
$0.52
$0.52
▼
$29.97
$1.42MN/A5.06 million shsN/A
Cardio Diagnostics Holdings, Inc. stock logo
CDIO
Cardio Diagnostics
$1.86
+1.6%		$1.84
$0.97
▼
$7.91
$5.42M2.2854,419 shs10,252 shs
CollPlant Biotechnologies Ltd. Sponsored ADR stock logo
CLGN
CollPlant Biotechnologies
$3.55
+4.0%		$3.32
$2.64
▼
$31.80
$4.93M1.7910.26 million shs236,429 shs
Soligenix Inc. stock logo
SNGX
Soligenix
$0.38
-0.8%		$0.38
$0.28
▼
$3.07
$5.68M1.92236,353 shs108,826 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abpro Holdings Inc. stock logo
ABP
Abpro
0.00%0.00%0.00%0.00%-93.20%
Cardio Diagnostics Holdings, Inc. stock logo
CDIO
Cardio Diagnostics
+1.64%+0.54%+6.29%-5.10%-52.19%
CollPlant Biotechnologies Ltd. Sponsored ADR stock logo
CLGN
CollPlant Biotechnologies
+4.04%-0.84%+14.48%-4.31%-86.45%
Soligenix Inc. stock logo
SNGX
Soligenix
-0.84%+0.85%-0.76%-14.28%-87.66%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abpro Holdings Inc. stock logo
ABP
Abpro
$0.52
$0.52
$0.52
▼
$29.97
$1.42MN/A5.06 million shsN/A
Cardio Diagnostics Holdings, Inc. stock logo
CDIO
Cardio Diagnostics
$1.86
+1.6%		$1.84
$0.97
▼
$7.91
$5.42M2.2854,419 shs10,252 shs
CollPlant Biotechnologies Ltd. Sponsored ADR stock logo
CLGN
CollPlant Biotechnologies
$3.55
+4.0%		$3.32
$2.64
▼
$31.80
$4.93M1.7910.26 million shs236,429 shs
Soligenix Inc. stock logo
SNGX
Soligenix
$0.38
-0.8%		$0.38
$0.28
▼
$3.07
$5.68M1.92236,353 shs108,826 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abpro Holdings Inc. stock logo
ABP
Abpro
0.00%0.00%0.00%0.00%-93.20%
Cardio Diagnostics Holdings, Inc. stock logo
CDIO
Cardio Diagnostics
+1.64%+0.54%+6.29%-5.10%-52.19%
CollPlant Biotechnologies Ltd. Sponsored ADR stock logo
CLGN
CollPlant Biotechnologies
+4.04%-0.84%+14.48%-4.31%-86.45%
Soligenix Inc. stock logo
SNGX
Soligenix
-0.84%+0.85%-0.76%-14.28%-87.66%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abpro Holdings Inc. stock logo
ABP
Abpro
1.50
ReduceN/AN/A
Cardio Diagnostics Holdings, Inc. stock logo
CDIO
Cardio Diagnostics
1.00
SellN/AN/A
CollPlant Biotechnologies Ltd. Sponsored ADR stock logo
CLGN
CollPlant Biotechnologies
1.50
Reduce$120.003,280.28% Upside
Soligenix Inc. stock logo
SNGX
Soligenix
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest ABP, SNGX, CDIO, and CLGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2026
Soligenix Inc. stock logo
SNGX
Soligenix
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/11/2026
Cardio Diagnostics Holdings, Inc. stock logo
CDIO
Cardio Diagnostics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/8/2026
CollPlant Biotechnologies Ltd. Sponsored ADR stock logo
CLGN
CollPlant Biotechnologies
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E) ➝ Sell (E+)
(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abpro Holdings Inc. stock logo
ABP
Abpro
N/AN/AN/AN/A($8.83) per shareN/A
Cardio Diagnostics Holdings, Inc. stock logo
CDIO
Cardio Diagnostics
$10K550.56N/AN/A$2.51 per share0.74
CollPlant Biotechnologies Ltd. Sponsored ADR stock logo
CLGN
CollPlant Biotechnologies
$2.37M21.63N/AN/A$0.48 per share7.40
Soligenix Inc. stock logo
SNGX
Soligenix
$120K46.93N/AN/A$0.45 per share0.84
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abpro Holdings Inc. stock logo
ABP
Abpro
-$7.23M-$4.23N/AN/AN/AN/AN/A-344.76%N/A
Cardio Diagnostics Holdings, Inc. stock logo
CDIO
Cardio Diagnostics
-$6.50M-$2.92N/AN/AN/A-43,133.33%-82.28%-76.03%11/6/2026 (Estimated)
CollPlant Biotechnologies Ltd. Sponsored ADR stock logo
CLGN
CollPlant Biotechnologies
-$11.49M-$1.45N/AN/AN/A-683.68%-218.81%-139.28%N/A
Soligenix Inc. stock logo
SNGX
Soligenix
-$11.08M-$0.98N/AN/AN/AN/A-180.25%-107.46%11/6/2026 (Estimated)

Latest ABP, SNGX, CDIO, and CLGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2026Q2 2026
Cardio Diagnostics Holdings, Inc. stock logo
CDIO
Cardio Diagnostics
N/A-$0.51N/A-$0.51N/A$0.01 million
8/7/2026Q2 2026
Soligenix Inc. stock logo
SNGX
Soligenix
-$0.1550-$0.12+$0.0350-$0.12N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Abpro Holdings Inc. stock logo
ABP
Abpro
N/AN/AN/AN/AN/A
Cardio Diagnostics Holdings, Inc. stock logo
CDIO
Cardio Diagnostics
N/AN/AN/AN/AN/A
CollPlant Biotechnologies Ltd. Sponsored ADR stock logo
CLGN
CollPlant Biotechnologies
N/AN/AN/AN/AN/A
Soligenix Inc. stock logo
SNGX
Soligenix
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abpro Holdings Inc. stock logo
ABP
Abpro
N/A
0.07
0.07
Cardio Diagnostics Holdings, Inc. stock logo
CDIO
Cardio Diagnostics
N/A
17.16
17.16
CollPlant Biotechnologies Ltd. Sponsored ADR stock logo
CLGN
CollPlant Biotechnologies
N/A
2.27
1.99
Soligenix Inc. stock logo
SNGX
Soligenix
N/A
2.77
2.77

Institutional Ownership

CompanyInstitutional Ownership
Abpro Holdings Inc. stock logo
ABP
Abpro
23.30%
Cardio Diagnostics Holdings, Inc. stock logo
CDIO
Cardio Diagnostics
8.06%
CollPlant Biotechnologies Ltd. Sponsored ADR stock logo
CLGN
CollPlant Biotechnologies
21.69%
Soligenix Inc. stock logo
SNGX
Soligenix
3.60%

Insider Ownership

CompanyInsider Ownership
Abpro Holdings Inc. stock logo
ABP
Abpro
13.70%
Cardio Diagnostics Holdings, Inc. stock logo
CDIO
Cardio Diagnostics
8.99%
CollPlant Biotechnologies Ltd. Sponsored ADR stock logo
CLGN
CollPlant Biotechnologies
9.60%
Soligenix Inc. stock logo
SNGX
Soligenix
1.91%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abpro Holdings Inc. stock logo
ABP
Abpro
152.72 million2.34 millionN/A
Cardio Diagnostics Holdings, Inc. stock logo
CDIO
Cardio Diagnostics
12.96 million2.69 millionNot Optionable
CollPlant Biotechnologies Ltd. Sponsored ADR stock logo
CLGN
CollPlant Biotechnologies
7014.44 million13.05 millionOptionable
Soligenix Inc. stock logo
SNGX
Soligenix
2014.82 million14.54 millionNot Optionable

Recent News About These Companies

SNGX: Applying for Vaccine Development Funding for Ebola Vaccine
August 12, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/sngx-applying-vaccine-development-funding-112500628.html
Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results
August 7, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/soligenix-announces-recent-updates-and-second-quarter-2026-financial-results-302845724.html
Soligenix Expands At-the-Market Equity Offering Capacity
June 26, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/soligenix-expands-at-the-market-equity-offering-capacity?utm_source=marketbeat.com&utm_medium=referral
Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine
June 8, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/soligenix-applying-for-vaccine-development-funding-for-bundibugyo-ebola-vaccine-302793388.html
Soligenix Expands At-The-Market Equity Financing Capacity
May 28, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/soligenix-expands-at-the-market-equity-financing-capacity?utm_source=marketbeat.com&utm_medium=referral
SNGX Stock More Than Doubles In Pre-Market, Eyes $1 Breakout For First Time In A Month – Ebola Vaccine Optimism Fuels Retail Frenzy
May 27, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/sngx-stock-more-doubles-pre-112801471.html
Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo
May 26, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/suitability-of-vaccine-platform-for-bundibugyo-virus-cause-of-the-ebola-outbreak-in-congo-302780813.html
SOLIGENIX, INC.: Soligenix Announces Recent Updates and First Quarter 2026 Financial Results
May 8, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68439993-soligenix-inc-soligenix-announces-recent-updates-and-first-quarter-2026-financial-results-008.htm
Soligenix Announces Recent Updates and First Quarter 2026 Financial Results
May 8, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/soligenix-announces-recent-updates-and-first-quarter-2026-financial-results-302766364.html
SNGX stock slumps to record low after lymphoma trial fails – all eyes now on Behçet’s disease treatment
April 29, 2026  |  msn.comhttps://www.msn.com/en-us/money/general/sngx-stock-slumps-to-record-low-after-lymphoma-trial-fails-all-eyes-now-on-beh%C3%A7et-s-disease-treatment/ar-AA21Vlpj
SNGX phase 3 trial halted on HyBryte
April 29, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/sngx-phase-3-trial-halted-on-hybryte/ar-AA21VuWj
SOLIGENIX, INC.: Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte in Treatment of Cutaneous T-Cell Lymphoma
April 28, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-04/68326767-soligenix-inc-soligenix-announces-interim-results-from-the-phase-3-flash2-trial-evaluating-hybryte-in-treatment-of-cutaneous-t-cell-lymphoma-008.htm
SNGX phase 3 trial halted — HyBryte setback puts strategy in question
April 28, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/sngx-phase-3-trial-halted-hybryte-setback-puts-strategy-in-question/ar-AA21VuWj
Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma
April 28, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/soligenix-announces-interim-results-from-the-phase-3-flash2-trial-evaluating-hybryte-in-treatment-of-cutaneous-t-cell-lymphoma-302754503.html
Soligenix (SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach
April 23, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/soligenix-sngx-highlights-patient-centric-190000456.html
Soligenix (NASDAQ: SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach
April 23, 2026  |  usatoday.comhttps://www.usatoday.com/press-release/story/30963/soligenix-nasdaq-sngx-highlights-patient-centric-drug-development-strategy-through-reformulation-approach/
Soligenix (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status
April 20, 2026  |  financial-news.co.ukhttps://www.financial-news.co.uk/soligenix-nasdaq-sngx-strengthens-pipeline-as-european-commission-grants-sgx945-orphan-status/
Soligenix (SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status
April 20, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/soligenix-sngx-strengthens-pipeline-european-182338961.html
Soligenix (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study Results
April 17, 2026  |  financial-news.co.ukhttps://www.financial-news.co.uk/soligenix-nasdaq-sngx-advances-ctcl-research-with-interim-analysis-comparative-study-results/
Soligenix (SNGX) Advances CTCL Research With Interim Analysis, Comparative Study Results
April 17, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/soligenix-sngx-advances-ctcl-research-183000890.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Abpro stock logo

Abpro NASDAQ:ABP

$0.52 0.00 (0.00%)
As of 09/3/2026

Abpro Holdings Inc. is a biotechnology company. The company's mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro Holdings Inc., formerly known as Atlantic Coastal Acquisition Corp. II, is based in WOBURN, Mass.

Cardio Diagnostics stock logo

Cardio Diagnostics NASDAQ:CDIO

$1.86 +0.03 (+1.64%)
As of 09/4/2026 04:00 PM Eastern

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.

CollPlant Biotechnologies stock logo

CollPlant Biotechnologies NASDAQ:CLGN

$3.55 +0.14 (+4.04%)
As of 09/4/2026 04:00 PM Eastern

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.

Soligenix stock logo

Soligenix NASDAQ:SNGX

$0.38 0.00 (-0.84%)
As of 09/4/2026 03:59 PM Eastern

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas